New tuberculosis drug development: Targeting the shikimate pathway

Senta M. Kapnick; Ying Zhang

doi:10.1517/17460441.3.5.565

New tuberculosis drug development: Targeting the shikimate pathway

Senta M. Kapnick, Ying Zhang

Bloomberg School of Public Health

Research output: Contribution to journal › Review article › peer-review

Abstract

Background: Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, yet no new drugs have been developed in the last 40 years. Objective: The exceedingly lengthy TB chemotherapy and the increasing emergence of drug resistance complicated by HIV co-infection call for the development of new TB drugs. These problems are further compounded by a poor understanding of the biology of persister bacteria. Methods: New molecular tools have offered insights into potential new drug targets, particularly the enzymes of the shikimate pathway, which is the focus of this review. Results/conclusion: Shikimate pathway enzymes, especially shikimate kinase, may offer attractive targets for new TB drug and vaccine development.

Original language	English (US)
Pages (from-to)	565-577
Number of pages	13
Journal	Expert Opinion on Drug Discovery
Volume	3
Issue number	5
DOIs	https://doi.org/10.1517/17460441.3.5.565
State	Published - May 2008

Keywords

Drug development
Mycobacterium tuberculosis
Shikimate kinase
Shikimate pathway

ASJC Scopus subject areas

Drug Discovery

Access to Document

10.1517/17460441.3.5.565

Fingerprint Dive into the research topics of 'New tuberculosis drug development: Targeting the shikimate pathway'. Together they form a unique fingerprint.

Cite this

@article{8be81517be464beba704bb5d94b75fb9,

title = "New tuberculosis drug development: Targeting the shikimate pathway",

abstract = "Background: Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, yet no new drugs have been developed in the last 40 years. Objective: The exceedingly lengthy TB chemotherapy and the increasing emergence of drug resistance complicated by HIV co-infection call for the development of new TB drugs. These problems are further compounded by a poor understanding of the biology of persister bacteria. Methods: New molecular tools have offered insights into potential new drug targets, particularly the enzymes of the shikimate pathway, which is the focus of this review. Results/conclusion: Shikimate pathway enzymes, especially shikimate kinase, may offer attractive targets for new TB drug and vaccine development.",

keywords = "Drug development, Mycobacterium tuberculosis, Shikimate kinase, Shikimate pathway",

author = "Kapnick, {Senta M.} and Ying Zhang",

note = "Funding Information: YZ acknowledges the support by NIH grant AI44063, Basic Research (973) Program (2005CB523102) and Changjiang Scholar Program, China.",

year = "2008",

month = may,

doi = "10.1517/17460441.3.5.565",

language = "English (US)",

volume = "3",

pages = "565--577",

journal = "Expert Opinion on Drug Discovery",

issn = "1746-0441",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - New tuberculosis drug development

T2 - Targeting the shikimate pathway

AU - Kapnick, Senta M.

AU - Zhang, Ying

N1 - Funding Information: YZ acknowledges the support by NIH grant AI44063, Basic Research (973) Program (2005CB523102) and Changjiang Scholar Program, China.

PY - 2008/5

Y1 - 2008/5

N2 - Background: Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, yet no new drugs have been developed in the last 40 years. Objective: The exceedingly lengthy TB chemotherapy and the increasing emergence of drug resistance complicated by HIV co-infection call for the development of new TB drugs. These problems are further compounded by a poor understanding of the biology of persister bacteria. Methods: New molecular tools have offered insights into potential new drug targets, particularly the enzymes of the shikimate pathway, which is the focus of this review. Results/conclusion: Shikimate pathway enzymes, especially shikimate kinase, may offer attractive targets for new TB drug and vaccine development.

AB - Background: Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, yet no new drugs have been developed in the last 40 years. Objective: The exceedingly lengthy TB chemotherapy and the increasing emergence of drug resistance complicated by HIV co-infection call for the development of new TB drugs. These problems are further compounded by a poor understanding of the biology of persister bacteria. Methods: New molecular tools have offered insights into potential new drug targets, particularly the enzymes of the shikimate pathway, which is the focus of this review. Results/conclusion: Shikimate pathway enzymes, especially shikimate kinase, may offer attractive targets for new TB drug and vaccine development.

KW - Drug development

KW - Mycobacterium tuberculosis

KW - Shikimate kinase

KW - Shikimate pathway

UR - http://www.scopus.com/inward/record.url?scp=44649177007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649177007&partnerID=8YFLogxK

U2 - 10.1517/17460441.3.5.565

DO - 10.1517/17460441.3.5.565

M3 - Review article

C2 - 23484927

AN - SCOPUS:44649177007

VL - 3

SP - 565

EP - 577

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 5

ER -